Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

Published:2009-03 Issue:2 Volume:23 Page:87-93
ISSN:0268-960X
Container-title:Blood Reviews
language:en
Short-container-title:Blood Reviews

Author:

Palumbo Antonio,Dimopoulos Meletios,Miguel Jesus San,Harousseau Jean-Luc,Attal Michel,Hussein Mohamad,Knop Stefan,Ludwig Heinz,von Lilienfeld-Toal Marie,Sonneveld Pieter

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference53 articles.

1. Towards a new age in the treatment of multiple myeloma;Piazza;Ann Hematol,2007

2. Review of 1027 patients with newly diagnosed multiple myeloma;Kyle;Mayo Clin Proc,2003

3. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in OncologyTM. Multiple Myeloma. V.1.2008. [accessed 4.10.2007].

4. UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005;Smith;Br J Haematol,2006

5. Thalidomide and lenalidomide in the treatment of multiple myeloma;Kumar;Eur J Cancer,2006

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patient with multiple myeloma;BMC Pulmonary Medicine;2024-07-04

2. Acute Hypoxic Respiratory Failure Due To Lenalidomide-Induced Interstitial Pneumonitis;2023-09-12

3. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma;New England Journal of Medicine;2022-12-15

4. Smoldering multiple myeloma – Past, present, and future;Blood Reviews;2021-07

5. Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma;Blood Advances;2020-09-21